{"nctId":"NCT01294436","briefTitle":"Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus","startDateStruct":{"date":"2011-02"},"conditions":["Type2 Diabetes","High Blood Sugar"],"count":728,"armGroups":[{"label":"Open label treatment","type":"EXPERIMENTAL","interventionNames":["Drug: Dapagliflozin"]}],"interventions":[{"name":"Dapagliflozin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Provision of informed consent prior to any study specific procedures\n* Men or women age ≥20 years old (Either gender needs to be 40% or higher of total number of treated subjects)\n* diagnosed with type2 DM ; ≥6.5% and ≤10% at 1 week before treatment started\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus,\n* FPG \\>240 mg/dL before treatment started\n* Subjects who have history of unstable or rapidly progressing renal disease\n* Subjects who have severe hepatic insufficiency and/or significant abnormal liver function\n* Significant cardiovascular history","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Participants With Adverse Events","description":"To evaluate the safety and tolerability of long-term treatment up to 52 weeks with the dosing regimen of dapagliflozin, where it started with 5 mg and titrated up to 10 mg depending on participant's condition of glycemic control, in regard to adverse events","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.1","spread":null},{"groupId":"OG001","value":"72.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Proportion of Participants With Serious Adverse Events","description":"To evaluate the safety and tolerability of long-term treatment up to 52 weeks with the dosing regimen of dapagliflozin, where it started with 5 mg and titrated up to 10 mg depending on participant's condition of glycemic control, in regard to serious adverse events","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":null},{"groupId":"OG001","value":"3.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Proportion of Participants With At Least One Episode of Hypoglycemia","description":"To evaluate the safety and tolerability of long-term treatment up to 52 weeks with the dosing regimen of dapagliflozin, where it started with 5 mg and titrated up to 10 mg depending on participant's condition of glycemic control, in regard to occurrence of hypoglycemia","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null},{"groupId":"OG001","value":"4.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Mean Change in Hematocrit","description":"To evaluate the safety and tolerability of long-term treatment up to 52 weeks with the dosing regimen of dapagliflozin, where it started with 5 mg and titrated up to 10 mg depending on participant's condition of glycemic control, in regard to the change in hematocrit","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.17","spread":"0.1396"},{"groupId":"OG001","value":"2.00","spread":"0.1115"}]}]}]},{"type":"PRIMARY","title":"Mean Change in Alanine Aminotransferase (ALT)","description":"To evaluate the safety and tolerability of long-term treatment up to 52 weeks with the dosing regimen of dapagliflozin, where it started with 5 mg and titrated up to 10 mg depending on participant's condition of glycemic control, in regard to the change in alanine aminotransferase","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.1","spread":"0.955"},{"groupId":"OG001","value":"-5.4","spread":"0.622"}]}]}]},{"type":"PRIMARY","title":"Mean Change in Aspartate Aminotransferase (AST)","description":"To evaluate the safety and tolerability of long-term treatment up to 52 weeks with the dosing regimen of dapagliflozin, where it started with 5 mg and titrated up to 10 mg depending on participant's condition of glycemic control, in regard to the change in aspartate aminotransferase","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.9","spread":"0.695"},{"groupId":"OG001","value":"-2.6","spread":"0.410"}]}]}]},{"type":"PRIMARY","title":"Mean Change in Blood Urea Nitrogen (BUN)","description":"To evaluate the safety and tolerability of long-term treatment up to 52 weeks with the dosing regimen of dapagliflozin, where it started with 5 mg and titrated up to 10 mg depending on participant's condition of glycemic control, in regard to the change in blood urea nitrogen","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"0.250"},{"groupId":"OG001","value":"2.3","spread":"0.168"}]}]}]},{"type":"PRIMARY","title":"Mean Change in Magnesium","description":"To evaluate the safety and tolerability of long-term treatment up to 52 weeks with the dosing regimen of dapagliflozin, where it started with 5 mg and titrated up to 10 mg depending on participant's condition of glycemic control, in regard to the change in magnesium (1 mEq/L equivalent to 0.50 mmol/L)","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.0074"},{"groupId":"OG001","value":"0.05","spread":"0.0064"}]}]}]},{"type":"PRIMARY","title":"Mean Change in Serum Uric Acid","description":"To evaluate the safety and tolerability of long-term treatment up to 52 weeks with the dosing regimen of dapagliflozin, where it started with 5 mg and titrated up to 10 mg depending on participant's condition of glycemic control, in regard to the change in serum uric acid","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.61","spread":"0.0578"},{"groupId":"OG001","value":"-0.50","spread":"0.0374"}]}]}]},{"type":"PRIMARY","title":"Mean Change in Seated Heart Rate","description":"To evaluate the safety and tolerability of long-term treatment up to 52 weeks with the dosing regimen of dapagliflozin, where it started with 5 mg and titrated up to 10 mg depending on participant's condition of glycemic control, in regard to the change in pulse","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"7.52"},{"groupId":"OG001","value":"0.2","spread":"7.95"}]}]}]},{"type":"PRIMARY","title":"Mean Change in Seated Diastolic Blood Pressure","description":"To evaluate the safety and tolerability of long-term treatment up to 52 weeks with the dosing regimen of dapagliflozin, where it started with 5 mg and titrated up to 10 mg depending on participant's condition of glycemic control, in regard to the change in blood pressure","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"8.16"},{"groupId":"OG001","value":"-2.1","spread":"8.73"}]}]}]},{"type":"PRIMARY","title":"Mean Change in Seated Systolic Blood Pressure","description":"To evaluate the safety and tolerability of long-term treatment up to 52 weeks with the dosing regimen of dapagliflozin, where it started with 5 mg and titrated up to 10 mg depending on participant's condition of glycemic control, in regard to the change in blood pressure","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.2","spread":"11.68"},{"groupId":"OG001","value":"-3.9","spread":"13.03"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Mean Change in HbA1c Levels","description":"To evaluate the efficacy of long-term treatment up to 52 weeks with the dosing regimen of dapagliflozin, where it started with 5 mg and titrated up to 10 mg depending on participant's condition of glycemic control, in regard to the change in HbA1c","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.66","spread":"11.68"},{"groupId":"OG001","value":"-0.68","spread":"13.03"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Mean Change in Body Weight","description":"To evaluate the efficacy of long-term treatment up to 52 weeks with the dosing regimen of dapagliflozin, where it started with 5 mg and titrated up to 10 mg depending on participant's condition of glycemic control, in regard to the change in body weight","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.58","spread":"11.68"},{"groupId":"OG001","value":"-2.06","spread":"13.03"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":249},"commonTop":["NASOPHARYNGITIS","POLLAKIURIA"]}}}